Results 51 to 60 of about 26,546 (243)

Distinct Biotypes of Visual Perception in Major Depressive Disorder

Advanced Science, EarlyView.
In a discover dataset (272 acute MDD patients), this work identifies a novel depression biotype characterized by impaired visual motion perception, using machine learning clustering. An independent dataset confirms the robustness of this biotype through cross‐validation and demonstrates its generalizability.
Zhuoran Cai, Xi‐Wen Hu, Yuyang Li, Zheng Lin, Yongjie Li, Yong‐Chun Cai, Tao Xu, Ke Jia, Jin‐Fang Han, Zhong‐Lin Tan, Dezhong Yao, Xue Mei Song, Sugai Liang, Georg Northoff   +13 more
wiley   +1 more source

Role of aripiprazole in treatment-resistant schizophrenia

Neuropsychiatric Disease and Treatment, 2012
Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to ...
Mossaheb N, Kaufmann RM
doaj  

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Exploring the role of autistic traits in treatment-resistant and clozapine-resistant schizophrenia: a comparative study

Frontiers in Psychiatry
BackgroundTreatment resistance in schizophrenia is a major clinical challenge. While autistic traits are often more pronounced in patients with treatment-resistant schizophrenia (TRS), limited data exist on clozapine-resistant schizophrenia (CRS).
Ahmet Selim Başaran, Nur Nihal Türkel, Buket Koparal, Aslı Kuruoğlu   +3 more
doaj   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar, Natasha Monte da Silva, Juliana Carla Gomes Rodrigues, André Maurício Ribeiro‐dos‐Santos, Sandro José de Souza, Ândrea Ribeiro‐dos‐Santos, João Farias Guerreiro, Sidney Emanuel Batista dos Santos, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos   +9 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

No adverse events were observed in clozapine‐treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan

Neuropsychopharmacology Reports, 2021
Aim As an emergency measure during the coronavirus disease pandemic, the monitoring interval for clozapine use was temporarily extended beyond the regulatory requirement in Japan, which is the safest monitoring interval worldwide. In this study, we aimed
Masahiro Hata, Michiko Fujimoto, Koji Kanai, Kenji Yoshiyama, Yoshitaka Nakatani, Daiji Nakabayashi, Saki Maemura, Shinya Kawata, Takaaki Hakozaki, Shuya Nishikura, Aiko Umemoto, Toru Sasada, Kazuhiko Iwata, Hideki Tanaka, Akiko Mamoto, Yuuki Toi, Norio Taniguchi, Makiko Saito, Yoshio Kimura, Kazuko Kishimoto, Megumi Hayami, Manabu Ikeda   +21 more
doaj   +1 more source

Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia [PDF]

Schizophrenia Research, 2019
To investigate the impact of a polygenic risk score for schizophrenia (PRS-SZ) and urbanicity on the risk of treatment-resistant schizophrenia (TRS) in people diagnosed with schizophrenia and to evaluate the association between PRS-SZ and TRS across levels of urbanicity.Cohort study of people born after 1981 with a first registered diagnosis of ...
Christiane Gasse, Theresa Wimberley, Yungpeng Wang, Ole Mors, Anders Børglum, Thomas Damm Als, Thomas Werge, Merete Nordentoft, David M. Hougaard, Henriette Thisted Horsdal   +9 more
openaire   +4 more sources

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source